BACKGROUND: Accumulating evidence indicates that oxytocin plays an important role in social interactions. Previous studies also suggest altered oxytocin function in patients with schizophrenia and depression. However, few studies have examined the central oxytocin levels in these disorders. METHODS: Cerebrospinal fluid (CSF) oxytocin levels were measured by ELISA in male participants consisting of 27 patients with schizophrenia, 17 with major depressive disorder (MDD), and 21 healthy controls. RESULTS: CSF oxytocin levels of patients with schizophrenia or MDD did not differ significantly with healthy controls. The antidepressant dose or the Hamilton depression rating scale score did not significantly correlate with the oxytocin levels in MDD patients. CSF oxytocin levels in schizophrenic patients significantly negatively correlated with second generation antipsychotic dose (r=-0.49, P=0.010) but not with first generation antipsychotic dose (r=-0.13, P=0.50). A significant correlation was observed between oxytocin levels and negative subscale of PANSS (r=-0.38, P=0.050). This correlation remained significant even after controlling for second generation antipsychotic dose (r=-0.47, P=0.016). CONCLUSIONS: We obtained no evidence of altered CSF oxytocin levels in patients with schizophrenia or those with MDD. However, lower oxytocin levels may be related to higher second generation antipsychotic dose and more severe negative symptoms in schizophrenia.
BACKGROUND: Accumulating evidence indicates that oxytocin plays an important role in social interactions. Previous studies also suggest altered oxytocin function in patients with schizophrenia and depression. However, few studies have examined the central oxytocin levels in these disorders. METHODS: Cerebrospinal fluid (CSF) oxytocin levels were measured by ELISA in male participants consisting of 27 patients with schizophrenia, 17 with major depressive disorder (MDD), and 21 healthy controls. RESULTS: CSF oxytocin levels of patients with schizophrenia or MDD did not differ significantly with healthy controls. The antidepressant dose or the Hamilton depression rating scale score did not significantly correlate with the oxytocin levels in MDDpatients. CSF oxytocin levels in schizophrenicpatients significantly negatively correlated with second generation antipsychotic dose (r=-0.49, P=0.010) but not with first generation antipsychotic dose (r=-0.13, P=0.50). A significant correlation was observed between oxytocin levels and negative subscale of PANSS (r=-0.38, P=0.050). This correlation remained significant even after controlling for second generation antipsychotic dose (r=-0.47, P=0.016). CONCLUSIONS: We obtained no evidence of altered CSF oxytocin levels in patients with schizophrenia or those with MDD. However, lower oxytocin levels may be related to higher second generation antipsychotic dose and more severe negative symptoms in schizophrenia.
Authors: Mary R Lee; Heidi J Wehring; Robert P McMahon; Fang Liu; Jared Linthicum; Joseph G Verbalis; Robert W Buchanan; Gregory P Strauss; Leah H Rubin; Deanna L Kelly Journal: Schizophr Res Date: 2016-02-12 Impact factor: 4.939
Authors: Rebekah Wigton; Jocham Radua; Paul Allen; Bruno Averbeck; Andreas Meyer-Lindenberg; Philip McGuire; Sukhi S Shergill; Paolo Fusar-Poli Journal: J Psychiatry Neurosci Date: 2015-01 Impact factor: 6.186
Authors: Ellen R Bradley; Alison Seitz; Andrea N Niles; Katherine P Rankin; Daniel H Mathalon; Aoife O'Donovan; Joshua D Woolley Journal: Schizophr Res Date: 2019-08-12 Impact factor: 4.939
Authors: Lucas G Speck; Johanna Schöner; Felix Bermpohl; Andreas Heinz; Jürgen Gallinat; Tomislav Majic; Christiane Montag Journal: Soc Cogn Affect Neurosci Date: 2019-01-04 Impact factor: 3.436